Identification of potential modulators for human GPD1 by docking-based virtual screening, molecular dynamics simulations, binding free energy calculations, and DeLA-drug analysis.

Publication date: Jun 19, 2024

Cytosolic Glycerol-3-phosphate dehydrogenase 1 (GPD1, EC 1. 1.1. 8) plays a pivotal role in regulating the Embden-Meyerhof glucose glycolysis pathway (E-M pathway), as well as in conditions such as Huntington’s disease, cancer, and its potential role as a specific marker for Dormant Glioma Stem Cells. In this study, we conducted virtual screening using the ZINC database ( http://zinc. docking. org/ ) and the GPD1 structure to identify potential GPD1 modulators. The investigation involved screening active candidate ligands using ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) parameters, combined with molecular docking, pose analysis, and interaction analysis based on Lipinski and Veber criteria. Subsequently, the top 10 ligands were subjected to 200 ns all-atom molecular dynamics (M. D.) simulations, and binding free energies were calculated. The findings revealed that specific residues, namely TRP14, PRO94, LYS120, ASN151, THR264, ASP260, and GLN298, played a crucial role in ensuring system stability. Furthermore, through a comprehensive analysis involving molecular docking, molecular M. D., and DeLA-Drug, we identified 10 promising small molecules. These molecules represent potential lead compounds for developing effective therapeutics targeting GPD1-associated diseases, thereby contributing to a deeper understanding of GPD1-associated mechanisms. This study’s significance lies in identifying key residues associated with GPD1 and discovering valuable small molecules, providing a foundation for further research and development.

Open Access PDF

Concepts Keywords
Cancer Binding Sites
Dehydrogenase Glycerolphosphate Dehydrogenase
Glucose Glycerolphosphate Dehydrogenase
Lies GPD1
Pro94 Humans
Ligands
Ligands
Molecular docking
Molecular Docking Simulation
Molecular Dynamics Simulation
Molecular dynamics simulation
Protein Binding
Thermodynamics
Virtual screening

Semantics

Type Source Name
drug DRUGBANK Glycerin
drug DRUGBANK Phosphate ion
drug DRUGBANK Dextrose unspecified form
pathway REACTOME Glycolysis
disease MESH Huntington’s disease
disease MESH cancer
disease MESH Glioma
pathway KEGG Glioma
drug DRUGBANK Zinc
drug DRUGBANK Coenzyme M
disease MESH Brain tumor
drug DRUGBANK Dihydroxyacetone phosphate
drug DRUGBANK Flavin adenine dinucleotide
drug DRUGBANK NADH
disease MESH obesity
disease MESH pathogenesis
disease MESH neurodegenerative disorder
disease MESH carcinoma
drug DRUGBANK Green tea leaf
drug DRUGBANK Ginkgo biloba
drug DRUGBANK Water
drug DRUGBANK Tropicamide
drug DRUGBANK Oxygen
drug DRUGBANK Calcium
drug DRUGBANK L-Lysine
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
drug DRUGBANK Tenocyclidine
disease MESH shock
disease MESH prostate cancer
pathway KEGG Prostate cancer

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *